BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu M, Huang Q, Xie Y, Wu X, Ma H, Zhang Y, Xia Y. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation. J Hematol Oncol 2022;15:24. [PMID: 35279217 DOI: 10.1186/s13045-022-01242-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 16.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu K, Sun Q, Liu Q, Li H, Zhang W, Sun C. Focus on immune checkpoint PD-1/PD-L1 pathway: New advances of polyphenol phytochemicals in tumor immunotherapy. Biomedicine & Pharmacotherapy 2022;154:113618. [DOI: 10.1016/j.biopha.2022.113618] [Reference Citation Analysis]
2 Wang Y, Yang Q, Liu J, Shen X, Tai G, Gu H, Cao D. Comprehensive Curative Effect of Targeting PD-1 or Traditional Single-Agent Chemotherapy in Second-Line Therapy for Terminal or Metastatic Esophageal Cancer: A Systematic Review and Meta-Analysis. Journal of Oncology 2022;2022:1-12. [DOI: 10.1155/2022/4033863] [Reference Citation Analysis]
3 Li W, Wang F, Guo R, Bian Z, Song Y. Targeting macrophages in hematological malignancies: recent advances and future directions. J Hematol Oncol 2022;15:110. [PMID: 35978372 DOI: 10.1186/s13045-022-01328-x] [Reference Citation Analysis]
4 Li Y, Hu D, Pan M, Qu Y, Chu B, Liao J, Zhou X, Liu Q, Cheng S, Chen Y, Wei Q, Qian Z. Near-infrared light and redox dual-activatable nanosystems for synergistically cascaded cancer phototherapy with reduced skin photosensitization. Biomaterials 2022. [DOI: 10.1016/j.biomaterials.2022.121700] [Reference Citation Analysis]
5 Liu Z, Yu X, Xu L, Li Y, Zeng C. Current insight into the regulation of PD-L1 in cancer. Exp Hematol Oncol 2022;11:44. [PMID: 35907881 DOI: 10.1186/s40164-022-00297-8] [Reference Citation Analysis]
6 Jogalekar MP, Rajendran RL, Khan F, Dmello C, Gangadaran P, Ahn B. CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments. Front Immunol 2022;13:925985. [DOI: 10.3389/fimmu.2022.925985] [Reference Citation Analysis]
7 Ma H, Wu X, Li Y, Xia Y. Research Progress in the Molecular Mechanisms, Therapeutic Targets, and Drug Development of Idiopathic Pulmonary Fibrosis. Front Pharmacol 2022;13:963054. [DOI: 10.3389/fphar.2022.963054] [Reference Citation Analysis]
8 Huang Q, Wu M, Wu X, Zhang Y, Xia Y. Muscle-to-tumor crosstalk: The effect of exercise-induced myokine on cancer progression. Biochim Biophys Acta Rev Cancer 2022;1877:188761. [PMID: 35850277 DOI: 10.1016/j.bbcan.2022.188761] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Thuru X, Magnez R, El-bouazzati H, Vergoten G, Quesnel B, Bailly C. Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors. Cancers 2022;14:3368. [DOI: 10.3390/cancers14143368] [Reference Citation Analysis]
10 Guo Y, Yang J, Gao H, Tian X, Zhang X, Kan Q. Development and Verification of a Combined Immune- and Metabolism-Related Prognostic Signature for Hepatocellular Carcinoma. Front Immunol 2022;13:927635. [DOI: 10.3389/fimmu.2022.927635] [Reference Citation Analysis]
11 Xu L, Zou C, Zhang S, Chu TSM, Zhang Y, Chen W, Zhao C, Yang L, Xu Z, Dong S, Yu H, Li B, Guan X, Hou Y, Kong FM. Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors. J Hematol Oncol 2022;15:87. [PMID: 35799264 DOI: 10.1186/s13045-022-01307-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Zhu C, Ma H, He A, Li Y, He C, Xia Y. Exercise in cancer prevention and anticancer therapy: Efficacy, molecular mechanisms and clinical information. Cancer Letters 2022. [DOI: 10.1016/j.canlet.2022.215814] [Reference Citation Analysis]
13 Li H, Huang H, Zhang T, Feng H, Wang S, Zhang Y, Ji X, Cheng X, Zhao R. Apatinib: A Novel Antiangiogenic Drug in Monotherapy or Combination Immunotherapy for Digestive System Malignancies. Front Immunol 2022;13:937307. [DOI: 10.3389/fimmu.2022.937307] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Mei J, Wang H, Fan H, Ding J, Xu J. Case Report: Successful Immunotherapy Improved the Prognosis of the Unfavorable Subset of Cancer of Unknown Primary. Front Immunol 2022;13:900119. [DOI: 10.3389/fimmu.2022.900119] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Liu J, Zhang Y. Intratumor microbiome in cancer progression: current developments, challenges and future trends. Biomark Res 2022;10:37. [PMID: 35642013 DOI: 10.1186/s40364-022-00381-5] [Reference Citation Analysis]